Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors
| Autor: | Gaetano Paolino, Irene Esposito, Seung‐Mo Hong, Olca Basturk, Paola Mattiolo, Takuma Kaneko, Nicola Veronese, Aldo Scarpa, Volkan Adsay, Claudio Luchini |
|---|---|
| Přispěvatelé: | Paolino, Gaetano, Esposito, Irene, Hong, Seung-Mo, Basturk, Olca, Mattiolo, Paola, Kaneko, Takuma, Veronese, Nicola, Scarpa, Aldo, Adsay, Volkan, Luchini, Claudio |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Histology
IPMN ITPN Pancreatic Intraductal Neoplasms PDAC pancreatic ductal adenocarcinoma General Medicine Carcinoma Papillary Pathology and Forensic Medicine Pancreatic Neoplasms pancrea tubulopapillary Tubulopapillary Humans intraductal Precision Medicine Intraductal pancreas Pancreas Carcinoma Pancreatic Ductal |
| Popis: | Aims Intraductal tubulopapillary neoplasm (ITPN) of the pancreas is a recently recognized pancreatic tumor entity. Here we aimed to determine the most important features with a systematic review coupled with an integrated statistical approach. Methods and results PubMed, SCOPUS, and Embase were searched for studies reporting data on pancreatic ITPN. The clinicopathological, immunohistochemical, and molecular data were summarized. Then a comprehensive survival analysis and a comparative analysis of the molecular alterations of ITPN with those of pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) from reference cohorts (including the International Cancer Genome Consortium- ICGC dataset and The Cancer Genome Atlas, TCGA program) were conducted. The core findings of 128 patients were as follows: (i) Clinicopathological parameters: pancreatic head is the most common site; presence of an associated adenocarcinoma was reported in 60% of cases, but with rare nodal metastasis. (ii) Immunohistochemistry: MUC1 (>90%) and MUC6 (70%) were the most frequently expressed mucins. ITPN lacked the intestinal marker MUC2; unlike IPMN, it did not express MUC5AC. (iii) Molecular landscape: Compared with PDAC/IPMN, the classic pancreatic drivers KRAS, TP53, CDKN2A, SMAD4, GNAS, and RNF43 were less altered in ITPN (P < 0.001), whereas MCL amplifications, FGFR2 fusions, and PI3KCA mutations were commonly altered (P < 0.001). (iv) Survival analysis: ITPN with a "pure" branch duct involvement showed the lowest risk of recurrence. Conclusion ITPN is a distinct pancreatic neoplasm with specific clinicopathological and molecular characteristics. Its recognition is fundamental for its clinical/prognostic implications and for the enrichment of potential targets for precision oncology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|